Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results


1.		Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				PANC0002 95533, CPTK787AUS08, NCT00185588, PANC0002, NCT00185588


2.		PTK/ZK in Disseminated Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				UKSH A-105 EudraCT No. 2005-002192-32, NCT00615160

Last Modified: 10/16/2008 First Published: 10/25/2003


3.		Phase II Study of Vatalanib in Patients With Primary or Secondary Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				CALGB-10105 CALGB-10105, NCT00072475


4.		PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				05-0639 IND#: 72,721, NCT00240162

Last Modified: 5/10/2007 First Published: 6/23/2006


5.		Phase II Study of Vatalanib in Patients With Recurrent or Progressive Meningioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				NU-05C4 NU-1398-025, NOVARTIS-NU-05C4, NCT00348790


6.		PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				7416 CPTK787AUS39, NCT00511043


7.		Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				PTK787/ZK222584 LSU IRB-6355, NCT00590343


8.		The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				CPTK787/ZK222584 NCT00627198


9.		Trial of PTK787/ZK 222584 Plus Paclitaxel

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				05-046 NCT00358163

Last Modified: 5/12/2007 First Published: 10/14/2006


10.		Phase I Study of Vatalanib and Pemetrexed Disodium in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				MAYO-MC0515 MAYO-06-002065, NOVARTIS-CPTK787AUS16, NCT00390000

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute